Alterations of transforming growth factor beta 1 (TGF-beta 1) and TGF betareceptor expressions with progression in Dunning rat prostatic adenocarcinoma sublines
P. Wikstrom et al., Alterations of transforming growth factor beta 1 (TGF-beta 1) and TGF betareceptor expressions with progression in Dunning rat prostatic adenocarcinoma sublines, UROL RES, 27(3), 1999, pp. 185-193
Transforming growth factor-beta 1 (TGF-beta 1) inhibits epithelial cell pro
liferation in the normal prostate. Prostate tumours express high levels of
TGF-beta 1, and seem to acquire resistance to its anti-proliferative effect
s with tumour progression. In this study, TGF beta variations with tumour p
rogression were examined in the Dunning prostatic adenocarcinoma model. Exp
ression of TGF-beta 1 and TGF beta receptor type I and type II (TGF beta-RI
and TGF beta-RII) in rat dorsolateral prostate (DLP) and Dunning tumour su
blines (PAP, AT-1, AT-2, AT-3 and MatLyLu) was examined in vitro and in viv
o, using competitive reverse transcription-polymerase chain reaction (RT-PC
R), Northern and Western blot, and immunohistochemistry. All tumours expres
sed elevated levels of TGF-beta 1 and TGF beta-RI mRNA, when compared with
the DLP (P less than or equal to 0.05). All rumours except MatLyLu also exp
ressed elevated levels of TGF beta-RII mRNA (P less than or equal to 0.05).
Interestingly, TGF beta-RII protein levels were very low in the highly met
astatic AT-3 and MatLyLu rumours in vivo, when compared with levels in the
PAP, AT-1, and AT-2 rumours. This difference was not detected for the AT-1,
AT-2, and AT-3 cells in vitro. Immunostaining of TGF-beta 1, TGF beta-RI,
and TGF beta-RII was localised principally in normal and tumour epithelial
cells, and occasionally in smooth muscle cells. In conclusion, high express
ion of TGF-beta 1 and TGF beta-RI and low expression of TGF beta-RII may co
ntribute to tumour progression and metastasis in the Dunning prostatic aden
ocarcinoma model.